Artivion, Inc. (NYSE:AORT – Get Free Report) reached a new 52-week low during trading on Friday. The stock traded as low as $19.04 and last traded at $19.0780, with a volume of 81,041 shares trading hands. The stock had previously closed at $19.40.
Analyst Upgrades and Downgrades
A number of research firms have recently weighed in on AORT. Weiss Ratings restated a “sell (d-)” rating on shares of Artivion in a research report on Wednesday, November 4th. Needham & Company LLC reiterated a “buy” rating and issued a $44.00 price target on shares of Artivion in a report on Monday, July 20th. Jefferies Financial Group initiated coverage on Artivion in a research report on Tuesday, October 20th. They issued a “buy” rating and a $31.00 price objective for the company. Citizens Jmp dropped their price objective on Artivion from $48.00 to $42.00 and set a “market outperform” rating for the company in a report on Friday, November 6th. Finally, Wall Street Zen downgraded shares of Artivion from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $39.00.
Check Out Our Latest Stock Report on AORT
Artivion Price Performance
The company has a debt-to-equity ratio of 0.82, a quick ratio of 3.02 and a current ratio of 4.42. The company has a market capitalization of $932.47 million, a price-to-earnings ratio of -53.09 and a beta of 1.31. The company has a 50-day moving average price of $22.89 and a 200-day moving average price of $28.40.
Artivion (NYSE:AORT – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported $0.08 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.14. The business had revenue of $123.79 million for the quarter, compared to the consensus estimate of $120.97 million. Artivion had a negative net margin of 3.65% and a positive return on equity of 5.12%.
Insider Buying and Selling at Artivion
In other news, SVP Andrew M. Green sold 11,480 shares of the business’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $24.97, for a total value of $286,655.60. Following the completion of the transaction, the senior vice president owned 40,160 shares of the company’s stock, valued at $1,002,795.20. The trade was a 22.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO James P. Mackin sold 70,000 shares of the company’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $28.95, for a total transaction of $2,026,500.00. Following the completion of the sale, the chief executive officer owned 877,275 shares of the company’s stock, valued at approximately $25,397,111.25. This represents a 7.39% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 89,483 shares of company stock worth $2,529,531. Company insiders own 6.30% of the company’s stock.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in AORT. BlackRock Inc. bought a new stake in shares of Artivion in the second quarter worth about $149,965,000. Dimensional Fund Advisors LP lifted its holdings in shares of Artivion by 4.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,027,575 shares of the company’s stock valued at $37,626,000 after purchasing an additional 46,738 shares in the last quarter. GW&K Investment Management LLC lifted its holdings in shares of Artivion by 67.7% during the 3rd quarter. GW&K Investment Management LLC now owns 1,332,672 shares of the company’s stock valued at $30,412,000 after purchasing an additional 538,194 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Artivion by 9.0% during the 2nd quarter. Wellington Management Group LLP now owns 1,260,279 shares of the company’s stock valued at $28,318,000 after purchasing an additional 103,592 shares in the last quarter. Finally, Royce & Associates LP grew its position in shares of Artivion by 39.2% in the 3rd quarter. Royce & Associates LP now owns 889,702 shares of the company’s stock valued at $20,303,000 after purchasing an additional 250,420 shares during the period. 86.37% of the stock is currently owned by institutional investors.
Artivion Company Profile
Artivion, Inc. is a medical device company focused on treating aortic disease and supporting cardiac and vascular surgery. Its products include aortic stent grafts and surgical grafts, mechanical heart valves, and BioGlue, a surgical adhesive used in cardiovascular procedures. The company was founded as CryoLife and adopted the Artivion name in 2022. It serves healthcare providers in the United States and international markets. Artivion is headquartered in Kennesaw, Georgia. Its chief executive officer is Pat Mackin.
Read More
- Five stocks we like better than Artivion
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.
